Phytandina's model is not extractive. We are building a biotech company where the communities that steward Andean biodiversity become co-beneficiaries of the value it generates.
Impact is not a side effect of what we do — it's the architecture. Scientific, economic, and ecological sustainability are inseparable in our model.
Ecuador is one of the world's most biodiverse countries. Yet the global ingredient industry extracts knowledge from the Global South while concentrating IP in the Global North. Phytandina reverses this dynamic — building the research infrastructure, IP ownership, and commercial relationships locally.
Our primary extraction feedstock is passion fruit seeds — an agro-industrial waste stream from Ecuador's maracuyá processing sector. We convert what was discarded into premium cosmeceutical ingredients. This is waste valorization in practice: no new land use, no primary extraction pressure on wild populations.
Our supply agreements are structured to include premium pricing for Andean smallholders who meet our agricultural standards. We are developing a traceability model that will eventually allow cosmeceutical buyers to verify the social and ecological credentials of every ingredient they source through us.
The longevity economy is the fastest-growing segment in life sciences. Phytandina enters at a critical inflection point — before the market standards are set, while Andean IP is still unclaimed.
Ingredient houses (Evonik, Givaudan, Seppic, BASF Care Chemicals), innovative cosmeceutical brands, and longevity supplement formulators. Market entry is through licensing — asset-light, scalable, margin-rich.
Every pillar of Phytandina's model maps to measurable SDG commitments. These are not claims — they are structural features of how we operate.
Company founded in Quito. HPLC lab protocols established. Piceatannol standardization achieved at ≥2%. Withaperuvin O characterized. Cartier Women's Initiative candidacy submitted.
Co-research agreements with academic partners. Keratinocyte bioassays for Piceatannol SIRT1 confirmation. Withaperuvin O SASP inhibition mechanism mapping. First scientific publications.
COSMOS-standard application submitted. First B2B ingredient licensing agreement executed. Pilot supply chain for European market entry. Pre-seed funding round close.
3+ licensed ingredients. Clinical efficacy data published. Supply chain for EU and US markets fully operational. Impact measurement framework published with farmer traceability dashboard.